Location of Repository

Inhibition of Protein Farnesylation Arrests Adipogenesis and Affects PPARγ Expression and Activation in Differentiating Mesenchymal Stem Cells

By Daniel Rivas, Rahima Akter and Gustavo Duque


Protein farnesylation is required for the activation of multiple proteins involved in cell differentiation and function. In white adipose tissue protein, farnesylation has shown to be essential for the successful differentiation of preadipocytes into adipocytes. We hypothesize that protein farnesylation is required for PPARγ2 expression and activation, and therefore for the differentiation of human mesenchymal stem cells (MSCs) into adipocytes. MSCs were plated and induced to differentiate into adipocytes for three weeks. Differentiating cells were treated with either an inhibitor of farnesylation (FTI-277) or vehicle alone. The effect of inhibition of farnesylation in differentiating adipocytes was determined by oil red O staining. Cell survival was quantified using MTS Formazan. Additionally, nuclear extracts were obtained and prelamin A, chaperon protein HDJ-2, PPARγ, and SREBP-1 were determined by western blot. Finally, DNA binding PPARγ activity was determined using an ELISA-based PPARγ activation quantification method. Treatment with an inhibitor of farnesylation (FTI-277) arrests adipogenesis without affecting cell survival. This effect was concomitant with lower levels of PPARγ expression and activity. Finally, accumulation of prelamin A induced an increased proportion of mature SREBP-1 which is known to affect PPARγ activity. In summary, inhibition of protein farnesylation arrests the adipogenic differentiation of MSCs and affects PPARγ expression and activity

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2220071
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2004). 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2
    2. (2005). Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies amongfatdepots,”AmericanJournalofPhysiology.Endocrinology and Metabolism,
    3. (2002). Age-related bone loss: old bone, new facts,”
    4. (2005). Altered prelamin a processing is a common mechanism leading to lipodystrophy,”
    5. (2002). and aging: does aging make fat go
    6. (2001). Causes of age-related bone loss and bone fragility: an alternative view,”
    7. (2000). Comparison of potential markers of farnesyltransferase inhibition,”
    8. (2002). Discoveries, drugs and skeletal disorders,”
    9. (2006). DNA damageresponsesinprogeroidsyndromesarisefromdefective maturation of prelamin A,” J o u r n a lo fC e l lS c i e n c e ,
    10. (2002). e c k a - C z e r n i k ,E .J .M o e r m a n ,D .F .G r a n t ,J .M .L e h m a n n
    11. (2002). Estrogens (E2) regulate expression and response of 1,25-dihydroxyvitamin D3 receptors in bone cells: changes with aging and hormone deprivation,”
    12. (2004). Fat’s loss is bone’s gain,”
    13. (2007). G.DuqueandD.Rivas,“Alendronatehasananaboliceffecton bone through the differentiation of mesenchymal stem cells,”
    14. (2004). Gene expression profiles of early adipogenesis in human mesenchymal stem cells,”
    15. (2003). HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation,”
    16. (2005). Inhibiting farnesylationofprogerinpreventsthecharacteristicnuclearblebbing of Hutchinson-Gilford progeria syndrome,”
    17. (2001). Insulin-induced adipocyte differentiation: activation of CREB rescues adipogenesis from the arrest caused by inhibition of prenylation,”
    18. (2000). Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?”
    19. (2002). Lamin expression in human adipose cells in relation to anatomical site and differentiation state,”
    20. (1999). Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy,”
    21. (2005). M a n o l a g a s ,a n dR .L .J i l k a ,“ R o s i g l i t a z o n ec a u s e sb o n el o s si n mice by suppressing osteoblast differentiation and bone formation,”
    22. (2002). Mesenchymal stem cells and osteoblast differentiation,”
    23. (2006). Nuclear lamin A inhibits adipocyte differentiation: implications for Dunnigan-type familial partial lipodystrophy,”
    24. (2007). Osteoporosis,” in Hazzard’s Textbook in Geriatric Medicine,W .R .H a z z a r d ,e ta l . ,E d s . ,c h a p t e
    25. (2004). PPARγinsufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,”
    26. (1997). Preadipocyte function and aging: links between age-related changes in cell dynamics and altered fat tissue function,”
    27. (2005). Prelamin A, Zmpste24, misshapen cell nuclei, and progeria-new evidence suggesting that protein farnesylation could be important for disease pathogenesis,”
    28. (2005). Proteomic analysis of primary cultures of human adipose-derived stem cells,”
    29. (2001). R.D.MoirandT.P.Spann,“Thestructureandfunctionofnuclear lamins: implications for disease,” Cellular and Molecular Life Sciences,
    30. (2004). Vitamin D treatment of senescence accelerated mice (SAM-P/6) induces several regulators of stromal cell plasticity,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.